BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
Want to see IL:BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
1.50
>-0.01(-6.00%)
At close: 4:00 PM EST
1.50
>-0.01(-6.00%)
Day’s Range― - ―
52-Week Range1.10 - 3.90
Previous CloseN/A
Volume20.50M
Average Volume (3M)4.64M
Market Cap
₪34.07M
Enterprise Value18.64M
Total Cash (Recent Filing)₪20.88M
Total Debt (Recent Filing)₪10.15M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
May 27, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,620,977,300
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)₪1.50M
Bulls Say, Bears Say
Bulls Say
Pipeline Clinical AdvancementAdvancing GLIX1 into first-in-human Phase 1/2a with supporting preclinical efficacy is a structural de-risking event for a clinical-stage biotech. Successful early clinical read‑outs can validate the mechanism, unlock partner milestone payments and broaden long-term commercialization options in a high‑need GBM indication.
Partnering/licensing Business ModelA partnership/licensing model reduces capital intensity and transfers late‑stage development and commercialization risk to larger pharma partners. Durable revenue streams can include upfronts, milestones, and royalties—supporting funding flexibility and lowering the need for sole‑funded expensive Phase 3 programs.
Balance Sheet Leverage ImprovedImproved leverage and equity exceeding debt provide structural financial stability relative to prior periods. This profile supports access to capital on less dilutive terms, preserves optionality for partnerships or milestone financing, and reduces immediate credit risk compared with a more levered peer.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow demonstrates ongoing reliance on external financing to fund operations and trials. Over the medium term this raises dilution risk, pressures management to secure milestone or licensing deals, and constrains reinvestment in multiple pipeline programs simultaneously.
Structural UnprofitabilitySustained operating losses and negative margins limit internal capital generation and mean returns on equity remain negative. Until a program reaches commercialization or consistent partnering revenues materialize, profitability is unlikely, constraining long‑term self‑funding and elevating financing and execution risk.
Sharp Revenue ContractionA dramatic TTM revenue decline undermines forecasting and makes cost‑base planning difficult. Revenue volatility reduces predictability of milestone/royalty receipts, increases dependence on sporadic licensing events, and can impair the company’s ability to sustain development timelines without raising additional capital.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.10 and its highest was 3.90 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪34.07M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is May 27, 2026 which is in 4 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on Mar 23, 2026. The company reported 0 earnings per share for the quarter, beating the consensus estimate of -0.29 by 0.29.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is -0.58.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,620,977,300 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report, beating expectations of -0.29. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.